AzTrials
AzTrials

Liver DiseasesTIMOLDNCT05255042

Tissue Models for Liver Disease

An observational study of Liver Diseases, run by University of Leicester at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The human immune response to bacterial and viral local and systemic infection are fairly well understood, but we lack details on the earliest phases. Better knowledge of these events would be important for the prevention and treatment of severe bacterial or viral disease. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Liver Diseases
What is being tested?
organ and tissue sample collection only
How many people
36 participants
Where
1 siteUnited Kingdom
Study dates
8 Sep 2021to 25 Jun 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The liver segment samples included in this project will be from patients undergoing elective surgery for a lesion in the liver in the HPB Unit of the Leicester General Hospital. No change in the surgical procedure or recruiting results from this study and the use of the samples.

Who may be able to join

  • The samples included in this project will be from patients undergoing elective surgery in the HPB Unit of the Leicester General Hospital.
  • Liver segment samples from radical surgery are adult age (18-80 years)
  • Presence of liver segment tissue in the discarded material after hepatopancreato-biliary surgery.

Who cannot join

  • The main exclusion criterion is acute invasive l infection, but these patients are automatically excluded from major surgery.
  • Samples from patients treated with antibiotics prior to explant or surgery will not be excluded, but samples will have to be tested for residual antibiotic activity.

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • UHL NHS Trust - Leicester General Hospital

    Leicester, LE5 4PW

Other trials in United Kingdom

About this study

The human immune response to bacterial and viral local and systemic infection are fairly well understood, but we lack details on the earliest phases. Better knowledge of these events would be important for the prevention and treatment of severe bacterial or viral disease. From models of infection, we have data showing that bacteria replicate in a specific type of cells in the liver from where the bacteria then seed to the blood to cause blood stream infection. In order to gain more relevant data for humans, we have developed a spleen and liver perfusion model using pig organs. This model confirms our previous work and most importantly will now allow us to study these events in human organs.

Primary Objectives: The primary objective of the study is to identify therapies acting on the initial events during invasive bacterial and viral infection.

Read more

Secondary Objectives: The secondary objective of this study is to provide novel in vitro and ex vivo models of human liver macrophages to study the impact of therapies for invasive infection.

The Primary Endpoint of the study is to increase the resistance of liver macrophages to infection at least tenfold after treatment.

The Primary Outcome Measure of the study is the reduction of bacterial or viral load at pre-determined time-points.

Read the detailed description

This is a preclinical research project and no patient intervention is planned. The project makes use of anonymised human tissue samples discarded during radical surgery. The liver segment samples included in this project will be from patients undergoing elective surgery for a lesion in the liver in the HPB Unit of the Leicester General Hospital. The sample size of 96 patiens (46 liver segments) has been determined by power calculations and is in line with the number of livers actually removed by elective liver surgery over the past years. No change in the surgical procedure or recruiting results from this study and the use of the samples. All the experimental work carried out on the liver samples will have no effect on the patient.

Experiments include ex vivo organ segment perfusion and infection with bacteria or viruses. Biopsies of the perfused 46 liver segments are processed for in vitro tissue slice and macrophage cell culture. The resulting primary cell cultures and tissue slices will be stored frozen for future research. All in vitro studies on the 46 liver segments, and the tissues and cells derived from them, will evaluate the effect of therapeutic interventions (antibodies, receptor antagonists, antibiotics and other molecules) on the capacity of liver cells to clear invasive bacteria or viruses. The experiments will be carried out each time a liver sample will be available.

The detailed technical description of the experimental strategy including the strategy for storage and discarding of the human tissue will be as follows:

  1. Liver segment ex vivo perfusion: This work is done to stabilise the organ, infect the organ and then to derive from it tissue slices and cells for primary cell culture. We have successfully set up a normo-thermic ex vivo porcine liver perfusion model. This expertise allowed us to define the parameters for organ collection, transport and perfusion of porcine livers for up to twenty-four hours and importantly develop and infection model. Infection showed conservation of capacity to remove bacteria from blood and good filtering capacity and, essential for this application, that also in the whole organ model specific subsets of macrophages are permissive to bacterial intracellular replication. In this experimental series we propose to perfuse explanted human liver segments. In contrast to pigs, we will use for perfusion of the human organ synthetic medium in order to neutralise or minimise acquired immunity. Histology, confocal microscopy, FACS analysis and bacterial and viral enumeration will be the main methodologies to analyse the perfused organ. The aim of this part of the work is to demonstrate that at the organ level bacteria and viruses are able to replicate in liver tissue macrophages pinpointing attention of anti-infective treatments to the prevention of these early steps potentially preventing invasive bacterial and viral disease. Samples from the 46 perfused organ segments will be the source of tissue slice cultures and primary cell cultures.
  2. Primary cell cultures: From the 46 human liver segments we will derive samples for primary culture of human tissue macrophages and other immune cells. Using the methodology in use for cells from mice and pigs, we will set up primary cultures of human hepatic immune cells and in particular macrophages. Immune cells including macrophages and neutrophils will be purified by different methodologies including by percoll gradient centrifugation, FACS and magnetic separation and cultured for up to seven days. Cultures will be tested for multiple parameters including cytokines, surface markers, anybody production and gene expression. To test interaction with bacteria or viruses, the cultured cells will be infected with a panel of bacterial and viral pathogens. Upon other methodology, confocal microscopy, FACS and RNAseq will be used monitor behaviour of bacterial and viral pathogens and host cells. Interventions with cytokines, chemokines, drugs, antibiotics and other compounds will be carried out to test tractability of the system. No genotyping of the organ will be performed. With the aim in mind to identify targets for intervention, the cell culture models are intended to provide detailed quantifiable parameters of the interaction of bacteria or viruses and immune cells in particular tissue macrophages in a controlled in vitro culture system. This is intended to allow the design of medium-throughput assays to test strategies modifying initiation of invasive disease. Cells will be stored in liquid nitrogen for further research.
  3. Organotypic slice cultures: From the 46 human liver segments we will derive, in addition to cells, also tissue samples for organotypic slice cultures. With the methodology well set up for brain slices and described for liver, we will culture organotypic human liver slice cultures. These organ slices are superior to cell cultures, as they maintain the multicellular spatial microarchitecture of the organ, which is particularly important when analysing tissue macrophages. As for brain slice cultures, we will infect the slices with bacterial or viral pathogens and monitor their migration within the tissue, the infection of cells and the reaction of the single host cells. The use of tissue slice culture should allow to specifically study the targeting and replication-permissive nature of specific subsets of immune cells including macrophages. A goal of the objective is to allow for detailed development of infectious foci in the liver including time laps confocal microscopy of infected liver slices. Testing in this model cytokines and other host derived molecules are expected to show the potential of interventions targeting specific subsets of immune cells including macrophages. Tissue slices will be stored in liquid nitrogen for further research.
Conditions
Liver Diseases
Being tested
organ and tissue sample collection only
Medical subject headings
Liver Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • organ and tissue sample collection onlyOther

    Collection of liver segments removed by radical surgery of hepatic lobes, but not submitted to pathology

Study groups in NCT05255042
Study groupRoleWhat they receive
Trial ParticipantsOverall Description of Trial Participants: The liver organ samples included in this project will be from patients undergoing elective surgery for a lesion in the liver in the HPB Unit of the Leicester General Hospital. No change in the surgical procedure or recruiting results from this study and the use of the samples. Inclusion Criteria: The samples included in this project will be from patients undergoing elective liver surgery in the HPB Unit of the Leicester General Hospital. The criteria for inclusion of liver segment samples from radical surgery are adult age and presence of hepatic tissue in the discarded material after hepato-pancreato-biliary surgery. Exclusion Criteria: The main exclusion criterion is acute invasive infection, but these patients are automatically excluded from major surgery. Vulnerable groups will not be recruited.
Receives: Other: organ and tissue sample collection only

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Reduction of the load and replication of infectious agents by host directed interventions

    Reduction of the number of infectious agents per gram of tissue by therapies acting on the initial events during invasive infection.

    Measured: 3.5 Years

Secondary outcomes (1)
  1. Protocol for seven-day survival of tissue slices and primary macrophage cell cultures

    Protocol for seven-day survival of tissue slices and primary macrophage cell cultures to study in vitro therapies for invasive infection

    Measured: 3.5 Years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Feb 2022
  2. Study start8 Sep 2021
  3. Primary completion25 Jun 2025
  4. Study completion25 Jun 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
36 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05255042
Sponsor's protocol ID
0814
Acronym
TIMOLD
Status last verified
Oct 2023
First submitted
6 Jan 2022
Last updated
11 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Wanford JJ, Hames RG, Carreno D, Jasiunaite Z, Chung WY, Arena F, Di Pilato V, Straatman K, West K, Farzand R, Pizza M, Martinez-Pomares L, Andrew PW, Moxon ER, Dennison AR, Rossolini GM, Oggioni MR. Interaction of Klebsiella pneumoniae with tissue macrophages in a mouse infection model and ex-vivo pig organ perfusions: an exploratory investigation. Lancet Microbe. 2021 Dec;2(12):e695-e703. doi: 10.1016/S2666-5247(21)00195-6.

    PubMed 34901898
  • Carreno D, Wanford JJ, Jasiunaite Z, Hames RG, Chung WY, Dennison AR, Straatman K, Martinez-Pomares L, Pareek M, Orihuela CJ, Restrepo MI, Lim WS, Andrew PW, Moxon ER, Oggioni MR. Splenic macrophages as the source of bacteraemia during pneumococcal pneumonia. EBioMedicine. 2021 Oct;72:103601. doi: 10.1016/j.ebiom.2021.103601. Epub 2021 Oct 4.

    PubMed 34619637

Questions about this trial

What is this clinical trial studying?

An observational study of Liver Diseases, run by University of Leicester at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Reduction of the load and replication of infectious agents by host directed interventions (time frame: 3.5 Years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05255042, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in